2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension

TSOC pulmonary hypertension committee

Research output: Contribution to journalArticle

Abstract

Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH.4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.

Original languageEnglish
Pages (from-to)1584-1609
Number of pages26
JournalJournal of the Formosan Medical Association
Volume118
Issue number12
DOIs
Publication statusPublished - 2019 Dec

Fingerprint

Cardiology
Taiwan
Pulmonary Hypertension
Guidelines
Connective Tissue Diseases
Vascular Resistance
Echocardiography
Heart Diseases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{c7c2587aa90f4bffa5bacefdfd88b670,
title = "2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH.4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.",
author = "{TSOC pulmonary hypertension committee} and Huang, {Wei Chun} and Hsu, {Chih Hsin} and Sung, {Shih Hsien} and Ho, {Wan Jing} and Chu, {Chun Yuan} and Chang, {Chih Ping} and Chiu, {Yu Wei} and Wu, {Chun Hsien} and Chang, {Wei Ting} and Lin Lin and Lin, {Shoa Lin} and Cheng, {Chin Chang} and Wu, {Yih Jer} and Wu, {Shu Hao} and Hsieh, {Tsu Yi} and Hsu, {Hsao Hsun} and Morgan Fu and Dai, {Zen Kong} and Kuo, {Ping Hung} and Hwang, {Juey Jen} and Cheng, {Shu Meng}",
year = "2019",
month = "12",
doi = "10.1016/j.jfma.2018.12.009",
language = "English",
volume = "118",
pages = "1584--1609",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Excerpta Medica Asia Ltd.",
number = "12",

}

2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension. / TSOC pulmonary hypertension committee.

In: Journal of the Formosan Medical Association, Vol. 118, No. 12, 12.2019, p. 1584-1609.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension

AU - TSOC pulmonary hypertension committee

AU - Huang, Wei Chun

AU - Hsu, Chih Hsin

AU - Sung, Shih Hsien

AU - Ho, Wan Jing

AU - Chu, Chun Yuan

AU - Chang, Chih Ping

AU - Chiu, Yu Wei

AU - Wu, Chun Hsien

AU - Chang, Wei Ting

AU - Lin, Lin

AU - Lin, Shoa Lin

AU - Cheng, Chin Chang

AU - Wu, Yih Jer

AU - Wu, Shu Hao

AU - Hsieh, Tsu Yi

AU - Hsu, Hsao Hsun

AU - Fu, Morgan

AU - Dai, Zen Kong

AU - Kuo, Ping Hung

AU - Hwang, Juey Jen

AU - Cheng, Shu Meng

PY - 2019/12

Y1 - 2019/12

N2 - Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH.4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.

AB - Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH.4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.

UR - http://www.scopus.com/inward/record.url?scp=85063333446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063333446&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2018.12.009

DO - 10.1016/j.jfma.2018.12.009

M3 - Article

AN - SCOPUS:85063333446

VL - 118

SP - 1584

EP - 1609

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 12

ER -